Physician profile

Daniel Kaplan

Neurology (Psychiatry & Neurology) · Tampa, FL

NPI 1013412014

$1,953.01

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$897.91
Travel and Lodging$451.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $1,056.68 2023-2024 Pro, Axsos, Variax
Csl Behring $341.50 2019-2022
Medtronic, INC. $160.92 2021-2023 Linq II
Ceribell, INC. $144.05 2024 Pocket Eeg Device
Neurelis, INC. $127.66 2020-2021
Penumbra, INC. $99.72 2024 Penumbra System
Janssen Pharmaceuticals, INC $22.48 2024 Tremfya

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Kaplan

$1,953.01

in general payments reported 2019-2025

Years
2019-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/7232407/daniel-kaplan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.